Search company, investor...

ugichem

ugichem.com

Founded Year

1998

Stage

Grant - II | Alive

Total Raised

$5.74M

Last Raised

$1.09M | 10 yrs ago

About ugichem

ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.

Headquarters Location

Mitterweg 24

Innsbruck, 6020,

Austria

+43 (0)512 282285 10

Missing: ugichem's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ugichem's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ugichem

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ugichem is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ugichem Patents

ugichem has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2007

1/29/2013

Ribosomal proteins, Membrane biology, Immunology, Cell biology, G protein coupled receptors

Grant

Application Date

10/23/2007

Grant Date

1/29/2013

Title

Related Topics

Ribosomal proteins, Membrane biology, Immunology, Cell biology, G protein coupled receptors

Status

Grant

ugichem Frequently Asked Questions (FAQ)

  • When was ugichem founded?

    ugichem was founded in 1998.

  • Where is ugichem's headquarters?

    ugichem's headquarters is located at Mitterweg 24, Innsbruck.

  • What is ugichem's latest funding round?

    ugichem's latest funding round is Grant - II.

  • How much did ugichem raise?

    ugichem raised a total of $5.74M.

  • Who are the investors of ugichem?

    Investors of ugichem include FFG, BioScience Ventures Group and V+ Management.

  • Who are ugichem's competitors?

    Competitors of ugichem include Biocytogen, Kythera Biopharmaceuticals, Arresto BioSciences, Elara Pharmaceuticals, Altair Therapeutics and 12 more.

Compare ugichem to Competitors

E
Elara Pharmaceuticals

Elara Pharmaceuticals is a Heidelberg, Germany-based biotech company focused on the development of drugs for the treatment of different cancers.

A
Affibody

Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing biotherapeutics based on its unique proprietary technology platforms: Affibody molecules and Albumod. The company is based in Solna, Sweden.

G
Greenovation Biotech

greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins

A
AutekBio

AutekBio is a biotech firm headquartered in the Bay Area, US.

N
Nano Carrier

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

C
CELBIO SpA

SiTec Consulting was established in 1996, on the basis of long experience in pharmaceutical R&D. The company developed a range of expertise working with pharmaceutical and biotech companies in the United States and in Europe.n SiTec Consulting offers pharmaceutical and biotechnology companies a variety of services in the areas of preformulation, drug development, drug delivery and formulation technologies evaluation, regulatory and cGLP/cGMP compliance. The company can actively collaborate with start-up pharmaceutical and drug delivery companies to provide scientific and strategic support in the establishment of the new company's activities. The company emphasize open communication, active involvement with the client and continuous feedback.n Networking is one of the company's assets, allowing us to cover the complex demands of the R&D process. The company have access to laboratories and equipment and resources, located at the Bioindustry Park Canavese, and at selected universities and research centers in Europe. This aims to give the possibility to conduct and manage experimental parts of projects at the company's clients' request.n The company value the importance of high quality training. In addition to the hands-on experience the company can provide to the company's clients, SiTec is an authorized representative of the Center for Professional Advancement, a worldwide private institution dedicated to the provision of continuing technical and scientific education at a professional level.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.